


Navigating Bispecific Therapies in Multiple Myeloma: Roadmap for Onboarding and Operationalization

A panel of academic and community practice pharmacists with experience using BsAb was convened to provide recommendations for operationalizing and managing BsAb therapy



Institutional integration & operationalization

- P&T workflow
- EHR & REMS
- Financial considerations



Patient selection

- Inpatient
- Outpatient

Key stakeholders¹


- Physicians
- Advanced practice providers
- Pharmacists
- Nursing
- Social work
- Critical care staff
- Emergency department staff
- Administrators

Additional considerations



Administration

- Drug admin/monitoring
- Caregiver considerations



Transitions

- Patient transitions



Management

- CRS/ICANS
- Other AEs
- GPRC5D AEs

AE, adverse event; BsAb, bispecific antibody; CRS, cytokine release syndrome; EHR, electronic health record; GPRC5D, G protein-coupled receptor family C group 5 member D; ICANS, Immune effector cell-associated neurotoxicity syndrome; MM, multiple myeloma; P&T, Pharmacy & Therapeutics; REMS, risk evaluation and mitigation strategy.

1. Mahmoudjafari Z, et al. Sept 2024; online first. Available here: <https://doi.org/10.6004/jadpro.2024.15.8.15>



Please click the icons for additional information.